Market Place
Sourcing Support
Oxford BioTherapeutics to Present at World ADC Conference 2024
31 Oct 2024 //
GLOBENEWSWIRE
Oxford BioTherapeutics Named Best Tech SME At Thames Valley Awards
22 Jul 2024 //
GLOBENEWSWIRE
Oxford Bio Announces Launch of Enhanced Discovery Platform, OGAP®-Verify
07 Mar 2024 //
GLOBENEWSWIRE
Oxford Bio Announces First Patient Dosed with OBT076 in Phase 1b Trial
18 Jan 2024 //
GLOBENEWSWIRE
Oxford Announces Partner BI Received FDA Fast Track Designation for BI 764532
29 Nov 2023 //
GLOBENEWSWIRE
Boehringer Ingelheim Dosed First Patient in Phase 2 Trial with BI 764532
24 Oct 2023 //
GLOBENEWSWIRE
Oxford Relocates UK Headquarters to Strategic and Cutting-Edge R&D Location
11 Oct 2023 //
GLOBENEWSWIRE
Oxford Announces Partner BI Received FDA Fast Track Designation for BI 764532
02 Oct 2023 //
GLOBENEWSWIRE
Oxford BioTherapeutics Initiates Phase Ib Clinical Trial for OBT076
05 Jul 2023 //
GLOBENEWSWIRE
Boehringer Ingelheim extends 2020 collab with Oxford BioTherapeutics
25 May 2023 //
ENPTS
Oxford and Boehringer Agree on 2 Year Extension to Multi-Year Collaboration
25 May 2023 //
GLOBENEWSWIRE
Oxford BioTherapeutics announces Phase 1b trial in collaboration with GORTEC
19 Apr 2023 //
GLOBENEWSWIRE
Oxford to Announce New Fully Integrated ADC Engine at World ADC Conference 2023
09 Mar 2023 //
GLOBENEWSWIRE
Oxford BioTherapeutics wins Tech Company of the Year
07 Mar 2023 //
GLOBENEWSWIRE
Oxford BioTherapeutics enters into Commercial License Agreement with Genmab
03 Oct 2022 //
PRNEWSWIRE
Oxford Bio Announces Research Collaboration with ImmunoGen to Develop Novel ADCs
13 Jun 2022 //
PRNEWSWIRE
Agenus Enters 3 New Clinical Collaborations
31 May 2022 //
CONTRACTPHARMA
Oxford Bio to Present Initial Positive Data from PI Trial at ASCO 2022
26 May 2022 //
PRNEWSWIRE
Oxford Bio Announces Collaboration with Agenus for OBT076 + Balstilimab
25 May 2022 //
PRNEWSWIRE
Oxford Bio to Present Potential Novel Mechanism with Checkpoint Inhibitors
07 Apr 2022 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.